Replies to post #9218 on Synaptogenix Inc (SNPX)

[XenaLives]

Perhaps you missed this part:

EPAD is co-funded by the Innovative Medicines Initiative (IMI) and Europe’s pharma industry organisation EFPIA, and 2019 will see the first patients being treated by this groundbreaking new alliance.

Anavex 2-73 trials in Rett Syndrome and Parkinson's Dementia will read out this year. I believe the P2b Alzheimer's trial will also read out this year although the company has not given a time line for this. All three of these trials are placebo controlled. EPAD will be using the same precision medicine trial format that Anavex used for its P2a.

The two year timeline for the Alzheimer's trial is for the P3 which is likely to become a P4 if all three P2 trials have positive results.

The Parkinson's Dementia trial has already submitted a request for extension. It is a 150 patient placebo controlled trial.

Anavex has a large group of industry renowned experts on board. It is not a scam. A lot of people simply don't understand 21st century medicine. Anavex is ahead of the curve in that regard, Neurotrope is still using 20th century trial protocol. 2-73 could be approved around the world before Bryostatin begins a P3.

https://www.anavex.com/our-team/